Title

Weight Loss Aid in an Exposed Population
Use of a Weight Loss Aid in a Population Exposed to Polybrominated Biphenyls (PBB)
  • Phase

    Phase 1/Phase 2
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Intervention/Treatment

    Orlistat ...
  • Study Participants

    100
This study will explore whether the use of orlistat results in weight loss that is accompanied by a reduction in the body burdens of polybrominated biphenyls (PBB) and other Persistent Organic Pollutants (POPs).
Millions of people living in Michigan were exposed to brominated flame retardants (polybrominated biphenyls or PBB) as a result of the largest agricultural disaster in US history. Over the past six years, Emory researchers have tested nearly 900 Michigan residents and determined that 60% still had PBB in their bodies from that disaster. PBB is stored in body fat and the researchers at Emory have been asked by community members if weight loss might reduce their body burdens of PBB and other lipophilic chemicals. In an effort to understand how PBB and other persistent organic pollutants (POPs) are eliminated, the researchers are conducting a randomized trial of orlistat versus placebo.

Orlistat is an over-the-counter product approved by the FDA for weight loss and works by increasing excretion of fat into the stool. Since PBB is stored in body fat, the researchers hypothesize that orlistat may reduce the body burden of PBB and other POPs. This study is a randomized, placebo-controlled trial of orlistat (at the dose available over-the-counter) plus diet and exercise for 6 months in a population with elevated PBB levels. Participants will be healthy overweight adults and orlistat will be taken as directed for the approved indication (weight loss).
Study Started
Sep 14
2018
Primary Completion
Jun 30
2022
Study Completion
Jun 30
2022
Last Update
Sep 15
2022

Drug Orlistat

Participants will be instructed to take one 60mg capsule of orlistat with each meal containing fat, up to three capsules daily, for six months. A multivitamin will be provided to be taken once daily, at bedtime.

  • Other names: Alli

Drug Placebo capsule

Participants will be instructed to take one placebo capsule to match 60mg of orlistat with each meal containing fat, up to three capsules daily, for six months. A multivitamin will be provided to be taken once daily, at bedtime.

Orlistat Weight Loss Aid Experimental

Participants randomized to take orlistat at the over-the-counter dose for six months. Diet and exercise plus a daily multivitamin will also be recommended and monitored.

Placebo Placebo Comparator

Participants randomized to take a placebo to match orlistat at the over-the-counter dose for six months. Diet and exercise plus a daily multivitamin will also be recommended and monitored.

Criteria

Inclusion Criteria:

current or recent (within the last five years) serum PBB level of ≥1ppb, or are a member of a sub-group likely to have high serum PBB (former chemical worker, family member of former chemical worker, lived on a farm with animals that were quarantined because of PBB exposure)
at least 18 years old
currently reside in Michigan
able to participate in examinations and laboratory tests (a lipid panel, liver function test, thyroid function and and creatinine levels) done at at a local health department or other medical health facility and to be able to engage in moderate physical activity (e.g. walking)
participants with undiagnosed abdominal pain or diarrhea, Crohn's disease, Ulcerative Colitis, Celiac Disease, treated diabetes or treated thyroid disorder, will only be eligible following consultation with their primary care provider
any participant using levothyroxine will be instructed to take their dosage 4 hours before or after Orlistat in order to maintain eligibility

Exclusion Criteria:

BMI<25
abnormal liver function
abnormal creatinine levels
abnormal thyroid levels (TSH)
have type 1 diabetes
have had an organ transplant
are pregnant or lactating
current use of weight-loss medications, oral steroids, Coumadin, warfarin or Cyclosporine
have a diagnosed problem absorbing food, or have an eating disorder
a history of bariatric surgery, pancreatitis, kidney stones, gall bladder disorder or a serious chronic disease (e.g. uncontrolled diabetes, congestive heart failure, chronic kidney disease)
allergies to any ingredients of the Orlistat over-the-counter (OTC) capsules
participants will become ineligible at any point during the study if they begin a medical regimen involving any of the above medications
No Results Posted